Headquartered in Delaware NJ, IDEXX Laboratories, Inc. (IDXX - Free Report) is a developer, manufacturer and distributer of products and services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The company also sells a series of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Currently, IDEXX has a Zacks Rank #3 (Hold) but that could change following its impressive fourth-quarter 2016 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The current Zacks Consensus Estimate is pegged at 51 cents per share. IDEXX’s reported fourth-quarter earnings per share came in at 58 cents, an increase of 21% year-over-year. On a constant currency adjusted basis, this figure improved 33% year over year after accounting for an adverse 6 cents per share impact related to net changes in foreign exchange.
Full year reported fourth-quarter earnings per share came in at $2.44, an increase of 19% year-over-year. On a constant currency adjusted basis, this figure improved 25% year over year. The Zacks Consensus Estimate for full-year EPS is pegged at $2.37.
Revenues: IDEXX posted revenues of $442.9 million, which has beaten the Zacks Consensus Estimate for revenues of $436 million by 1.5%.
Full year revenues came in at $1.77 billion which is in line with the Zacks Consensus Estimate of full-year 2016 revenue.
Key Stats: Among its four business segments, IDEXXdelivered fourth-quarter revenues of $379.5 million (up 13%) in CAG, $24.3 million (up 1%) in Water, $ 32.9million (down 1%) Livestock, Poultry and Dairy (LPD)and $1.76 billion (up 0.9%) in Other.
Major Factors: Management seemed upbeat about its graduation in the category of S&P 500. The company’s fourth quarter and full year performance displayed the power of innovation to improve the standard of care for pets and drive the growth of veterinary services. In the fiscal 2016, management placed a record number of premium chemistry instruments, premium hematology instruments and 1,575 IDEXX SediVueDx instruments, the industry's first-and-only in-house urine sediment analyzer.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this IDEXX earnings report later!
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Headquartered in Delaware NJ, IDEXX Laboratories, Inc. (IDXX - Free Report) is a developer, manufacturer and distributer of products and services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets. The company also sells a series of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Currently, IDEXX has a Zacks Rank #3 (Hold) but that could change following its impressive fourth-quarter 2016 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The current Zacks Consensus Estimate is pegged at 51 cents per share. IDEXX’s reported fourth-quarter earnings per share came in at 58 cents, an increase of 21% year-over-year. On a constant currency adjusted basis, this figure improved 33% year over year after accounting for an adverse 6 cents per share impact related to net changes in foreign exchange.
Full year reported fourth-quarter earnings per share came in at $2.44, an increase of 19% year-over-year. On a constant currency adjusted basis, this figure improved 25% year over year. The Zacks Consensus Estimate for full-year EPS is pegged at $2.37.
Revenues: IDEXX posted revenues of $442.9 million, which has beaten the Zacks Consensus Estimate for revenues of $436 million by 1.5%.
Full year revenues came in at $1.77 billion which is in line with the Zacks Consensus Estimate of full-year 2016 revenue.
Key Stats: Among its four business segments, IDEXXdelivered fourth-quarter revenues of $379.5 million (up 13%) in CAG, $24.3 million (up 1%) in Water, $ 32.9million (down 1%) Livestock, Poultry and Dairy (LPD)and $1.76 billion (up 0.9%) in Other.
Major Factors: Management seemed upbeat about its graduation in the category of S&P 500. The company’s fourth quarter and full year performance displayed the power of innovation to improve the standard of care for pets and drive the growth of veterinary services. In the fiscal 2016, management placed a record number of premium chemistry instruments, premium hematology instruments and 1,575 IDEXX SediVueDx instruments, the industry's first-and-only in-house urine sediment analyzer.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this IDEXX earnings report later!
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on IDXX - FREE